Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shirai, Keisuke
PV-10-MM-1201, NCT02557321: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma	Active, not recruiting	1/2	50	US	PV-10, Rose Bengal Disodium, Pembrolizumab	Provectus Biopharmaceuticals, Inc.	Melanoma	05/23	04/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors	Completed	1/2	45	US, RoW	Modakafusp Alfa, TAK-573, Pembrolizumab	Takeda	Neoplasms, Melanoma	11/23	11/23
Jaroscak, Jennifer
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
Woodruff, Kristina
No trials found
Hendricks, Kate
No trials found